Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Cancer Treatment and Research|November 17, 2023
Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian CancerDimitrios Nasioudis, Erin M George, Haineng Xu, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
Rapid Quantitative Analysis of Individual (18)FDG-PET ScansBarbara E. Swartz, Ken Thomas, Fiona Simpkins, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 17, 2021
Humanized Patient-Derived Xenograft Models of Ovarian CancerSarah B Gitto, Erin George, Sergey Medvedev, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 21, 2020
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatinLilie L Lin, David S Lakomy, Matthew S Ning, et al.
Gynecologic Oncology|June 10, 2023
Disparities in clinical trial participation in ovarian cancer: A real-world analysisAnna Jo Bodurtha Smith, Rafael Alvarez, Jonathan Heintz, et al.
Cancer Science|January 22, 2009
Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivoNick Devoogdt, Nabila Rasool, Ebony Hoskins, et al.
American Journal of Obstetrics and Gynecology|September 30, 2024
Disparities in clinical drug trial participation in endometrial cancer: a real-world analysisAnna Jo Bodurtha Smith, Sebastian Spataro, Jonathan Heintz, et al.
Oncogene|July 27, 2005
Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancerMitchell Kamrava, Fiona Simpkins, Emilyn Alejandro, et al.
Gynecologic Oncology|December 9, 2014
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)Fiona Simpkins, Richard Drake, Pedro F Escobar, et al.
Gynecologic Oncology|April 2, 2002
Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancerRobert E Bristow, Fiona Simpkins, Harpreet K Pannu, et al.
Pageof 8